Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3202-3208

  Koreth, John ^a   Stevenson, Kristen E ^a   Kim, Haesook T ^a   McDonough, Sean M ^a   Bindra, Bhavjot ^a   Armand, Philippe ^a   Ho, Vincent T ^a   Cutler, Corey ^a   Blazar, Bruce R ^b   Antin, Joseph H ^a   Soiffer, Robert J ^a   Ritz, Jerome ^a   Alyea III, Edwin P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUSULFAN; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; METHOTREXATE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LOADING DRUG DOSE; MALE; ORGAN DONOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNRELATED DONORS;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BORONIC ACIDS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LYMPHOCYTE DEPLETION; MALE; METHOTREXATE; MIDDLE AGED; PYRAZINES; TACROLIMUS; UNRELATED DONORS;

EID: 84866546465     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.0984     Document Type: Article

References (19)

1. Flowers ME, Inamoto Y, Carpenter PA, et al: Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versushost disease according to National Institutes of Health consensus criteria. Blood 117:3214-3219, 2011
2. Lee SJ, Klein J, Haagenson M, et al: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110:4576-4583, 2007 (Pubitemid 351377826)
3. Petersdorf EW, Gooley T, Malkki M, et al: Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 69:25-30, 2007 (suppl 1)
4. Ho VT, Kim HT, Liney D, et al: HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 37:845-850, 2006
5. Nakamae H, Storer BE, Storb R, et al: Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: A multicenter trial. Biol Blood Marrow Transplant 16:384-394, 2010
6. Woolfrey A, Klein JP, Haagenson M, et al: HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 17:885-892, 2011
7. Soiffer RJ, Lerademacher J, Ho V, et al: Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117:6963-6970, 2011
8. Nencioni A, Schwarzenberg K, Brauer KM, et al: Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108:551-558, 2006 (Pubitemid 44061355)
9. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107:3575-3583, 2006
10. Kim JS, Lee JI, Shin JY, et al: Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation 88:1349-1359, 2009
11. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al: Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101:8120-8125, 2004 (Pubitemid 38698064)
12. Sun K, Wilkins DE, Anver MR, et al: Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 106:3293-3299, 2005 (Pubitemid 41565932)
13. Vodanovic-Jankovic S, Hari P, Jacobs P, et al: NF-kappaB as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145. Blood 107:827-834, 2006 (Pubitemid 43076412)
14. Koreth J, Stevenson KE, Kim HT, et al: Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 114:3956-3959, 2009
15. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1994
16. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
17. Ho VT, Soiffer RJ: The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98:3192-3204, 2001
18. Ho V, Kim H, Windawi S, et al: HLA mismatch and clinical outcome after unrelated donor (URD) non-myeloablative hematopoeitic stem cell transplantation (NST). Biol Blood Marrow Transplant 11:S14, 2005 (suppl 1)
19. Cutler C, Antin JH: Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: An update. Curr Opin Hematol 17:500-504, 2010